Biovie's Long COVID Drug Stumbles Again — Can a Parkinson's Bright Spot Save This Tiny Biotech From Investor Fatigue?

Shares of Biovie Inc. (BIVI) cratered nearly 10% to $1.85 in pre-market trading after the company disclosed that its Phase 2 Long COVID trial failed to prove the drug worked better than a placebo across all measures in the broad patient group. For a $15 million micro-cap company with zero revenue and a troubled clinical track record, the miss raises hard questions about whether its lead drug can ever produce consistent, convincing evidence.

• A 203-Patient Study That Found Nothing Definitive. The trial tested bezisterim — a pill designed to reduce brain inflammation — in roughly 200 Long COVID patients with brain fog and fatigue, evaluating 22 different clinical measures with no single primary endpoint designated as the key success metric.

The study did not achieve statistical significance on any endpoint, and results observed in subgroup analyses may not be replicated in future trials. The company is framing positive subgroup findings as "hypothesis-generating," but in drug development, that language typically signals a reset, not a breakthrough.

• This Is the Second Big Clinical Disappointment for Bezisterim. BioVie previously blamed "protocol deviations" at trial sites for the failure of the same drug's Phase 3 Alzheimer's trial , a debacle that crashed the stock over 60% in November 2023 and triggered a securities fraud class-action lawsuit. Two high-profile misses for the same compound erode the scientific thesis that bezisterim works broadly across neuroinflammatory diseases.

• A Parkinson's Win Is Now Carrying the Entire Company. In August, bezisterim showed statistically significant improvements in both motor and non-motor Parkinson's symptoms versus placebo in a separate Phase 2 trial.

BioVie plans to use those results to design a potentially pivotal Phase 3 Parkinson's study. That program is now the only clinical asset with clean positive data — and the sole reason the stock doubled off its 52-week low of $0.82.

• Cash Runway Tightens the Clock. The company holds roughly $13 million in cash against just $296,000 in debt. But BioVie burned through $19 million in operating cash in fiscal 2025.

A $300 million mixed-securities shelf filing in June signals management knows dilution — issuing new shares to raise money, which shrinks existing investors' stakes — is coming. Shares outstanding already surged 392% in one year.

The Long COVID failure leaves Biovie a one-program story banking on Parkinson's data that is still years from a marketable product. Today's 8:30 a.m. ET conference call will determine whether investors see enough in the subgroup data to stay patient — or head for the exits.